Connect your AI

CorMedix CRMD Amortization expense related to capitalized debt issuance costs

Amortization expense related to capitalized debt issuance costs at other companies

Emergent BiosolutionsEBS

——

ICU MedicalICUI

——

Medline, Inc. MDLN

——

Phathom Pharmaceuticals, Inc.PHAT

——

Other financials

Income statement

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: CorMedix’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's amortization expense related to capitalized debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CorMedix's amortization expense related to capitalized debt issuance costs?: CorMedix (CRMD) reported amortization expense related to capitalized debt issuance costs of $99.5K in Q4 2025.